Entrepreneur Success Story

News Archive

OneSkin closes $2M Financing to reverse aging skin

OneSkin closes $2M Financing to reverse aging skin OneSkin Technologies is working on optimizing their technology of in vitro tissue aging and quantitative measurement of anti-aging molecule effects over the age of skin models. This platform will allow them to screen for molecules that molecules that truly rejuvenate skin or prevent aging.

Read more

Naked Biome closes $5M Series Seed Financing for microbiome treatment of acne

Naked Biome closes $5M Series Seed Financing for microbiome treatment of acne Led by dermatologist Dr. Emma Taylor, the Naked Biome team is developing microbiome-based acne therapeutics. They have now closed a $5 million seed round to get them through clinical proof-of-principle.

Read more

Celgene acquires Delinia

Celgene acquires Delinia Three weeks after their graduation party,¬†Delinia¬†announced they had been acquired by Celgene for $300M upfront and up to $475M in milestones. Delinia’s co-founder and CSO, Jeff Greve, began with a single bench at QB3@953 in 2014. Less than two years later, he has delivered an exciting autoimmune candidate to Celgene – now that’s awesome!  

Read more

Top Place in the First Annual Diabetes Innovation Challenge

Top Place in the First Annual Diabetes Innovation Challenge Enable Biosciences was awarded top place in the First Annual Diabetes Innovation Challenge held in Boston for the most innovative late-stage (pre-clinical through translational) technology for their breakthrough ultra-sensitivity antibody assay platform. Press Release

Read more

Nucleo Life Sciences

Nucleo Life Sciences will be expanding their team to broaden the number of formulation and drug development projects they are tackling. Borne out of Actera, another former QB3@953 company, Nucleo Life Sciences incubated with us for a little over one year before outgrowing our location.

Read more

Address

953 Indiana St.
San Francisco, CA 94107
Tel: (415)-347-8287

Sign-Up for our Newsletter